Arcutis Biotherapeutics (ARQT) reported earnings on Tue 28 Oct 25 (b/o)

• Arcutis Biotherapeutics reports Q3 2025 results with $99.2M in ZORYVE sales, $7.4M net income, issues 2026 revenue guidance, and outlines growth strategy at Investor Day presentation.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. 

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 342
• Incorporated in 2016 
• Headquartered in Westlake Village, California.
• https://www.arcutis.com

IPO: Jan 31, 2020

Ticker: ARQT

 

 

 

 

Arcutis Biotherapeutics announces third quarter 2025 results; provides initial 2026 full year net product sales guidance of $455-$470 mln

WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achieve sustainable growth and reported financial results for the quarter ended September 30, 2025.